Longeveron Inc. (NASDAQ:LGVN) Short Interest Update

Longeveron Inc. (NASDAQ:LGVN) saw a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 91,100 shares, an increase of 224.2% from the March 31st total of 28,100 shares. Based on an average trading volume of 2,010,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 9.3% of the company’s shares are sold short.

Longeveron Price Performance

LGVN opened at $1.67 on Friday. The firm has a market capitalization of $4.19 million, a PE ratio of -0.16 and a beta of 0.21. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.50 and a quick ratio of 1.50. The business’s 50-day moving average is $3.76 and its two-hundred day moving average is $11.14. Longeveron has a 1 year low of $1.60 and a 1 year high of $44.00.

Longeveron (NASDAQ:LGVN) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($2.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.10) by ($0.40). Longeveron had a negative return on equity of 209.14% and a negative net margin of 3,020.17%. The firm had revenue of $0.06 million during the quarter, compared to analysts’ expectations of $0.21 million. Research analysts anticipate that Longeveron will post -8.5 earnings per share for the current fiscal year.

Insider Activity at Longeveron

In related news, insider Joshua Hare bought 106,383 shares of the company’s stock in a transaction on Wednesday, April 10th. The shares were acquired at an average cost of $2.35 per share, for a total transaction of $250,000.05. Following the purchase, the insider now directly owns 590,727 shares of the company’s stock, valued at $1,388,208.45. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, insider Joshua Hare purchased 106,383 shares of the business’s stock in a transaction dated Wednesday, April 10th. The shares were purchased at an average price of $2.35 per share, for a total transaction of $250,000.05. Following the completion of the purchase, the insider now owns 590,727 shares in the company, valued at approximately $1,388,208.45. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Rock Soffer acquired 31,915 shares of the firm’s stock in a transaction that occurred on Thursday, April 11th. The stock was purchased at an average price of $2.35 per share, with a total value of $75,000.25. Following the completion of the acquisition, the director now directly owns 208,534 shares of the company’s stock, valued at $490,054.90. The disclosure for this purchase can be found here. Insiders acquired a total of 148,936 shares of company stock worth $350,000 in the last quarter. 24.34% of the stock is owned by company insiders.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Longeveron stock. Armistice Capital LLC purchased a new position in Longeveron Inc. (NASDAQ:LGVN) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 1,836,000 shares of the company’s stock, valued at approximately $2,497,000. Armistice Capital LLC owned about 7.31% of Longeveron at the end of the most recent quarter. Hedge funds and other institutional investors own 10.01% of the company’s stock.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young, healthy adult donors.